Even when desmoid tumor patients seem to tolerate niragacestat well, they often report a surprising improvement in well-being after discontinuing the drug. This reveals a subtle, cumulative quality-of-life impact from low-grade toxicities that may not be fully appreciated by patients or clinicians during active treatment.

Hedgehog inhibitors for basal cell carcinoma cause significant side effects like dysgeusia and muscle cramps. To improve tolerability and long-term adherence, clinicians use practical strategies like scheduled treatment interruptions (e.g., weeks on, weeks off) rather than continuous daily dosing.

Despite subsequent data not confirming an increased bleeding risk compared to other therapies, the initial studies on pacritinib showed a signal for increased bleeding. Consequently, it is still advised that the drug be stopped for several days prior to any major surgical procedure as a safety precaution.

Broad-spectrum RAS-on inhibitors like daraxonrasib present skin toxicity as a dose-limiting side effect. However, this rash is clinically distinct from that caused by EGFR inhibitors. It is often manageable with brief treatment interruptions, frequently without requiring dose reductions, and patients tend to acclimate to it over time.

While newer ROS1 inhibitors have overlapping efficacy, their side effect profiles differ. Repotrectinib is more associated with neurological issues, while taletrectinib can cause more gastrointestinal distress. This allows clinicians to sequentially switch patients between these agents to find a tolerable long-term option.

A critical reason patients stop ADC treatments is the burden of side effects like skin toxicity or GI issues, not just disease progression. This underscores the urgent need to develop ADCs with better safety profiles, enabling patients to stay on effective therapy longer.

While both Talatrectinib and Repotrectinib show impressive efficacy in ROS1-positive NSCLC, the choice between them can hinge on their side effect profiles. Talatrectinib demonstrates lower rates of TRK-related adverse events like dizziness, offering a key advantage in clinical practice.

Newer ROS1 inhibitors can cause hyperphagia (extreme hunger) and substantial weight gain. This is a "bystander effect" from unintended inhibition of the TRK protein, which helps regulate appetite centers in the brain. This can be a distressing and hard-to-manage side effect for patients on long-term therapy.

Despite being advanced targeted therapies, TROP2-directed ADCs present complex safety profiles. Oncologists must manage classic chemotherapy side effects like nausea and cytopenias alongside unique, serious toxicities including stomatitis, ocular issues, and potentially fatal interstitial lung disease, requiring specialized patient monitoring and counseling.